Amount of eligible sufferers: CDEC talked over the uncertainty in the number of clients with reasonably extreme to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific authorities consulted by CADTH indicated that some sufferers who are categorised as acquiring gentle or reasonable disorder may have a critical bleeding